FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977332002> ?p ?o ?g. }

• W2977332002 endingPage "S75" @default.
• W2977332002 startingPage "S75" @default.
• W2977332002 abstract "Introduction: The CA 19.9 and carcinoembryonic antigen (CEA) are tumor markers used in the diagnosis of cholangiocarcinoma. CA 19-9 and CEA are elevated in up to 85% and 30% of cases, respectively. However, it is still unknown whether both have value in prognosis and survival of these patients. Aim: Evaluate the predictive value of serum levels of CA 19-9 antigen at diagnosis as a marker of survival and metastization. We also evaluated its relationship with other clinical and analytical variables. Methods: Retrospective study of 59 patients with the diagnosis of cholangiocarcinoma for whom serum CA19-9 levels were determined at diagnosis. A cutoff based on the median value of the sample was established. Results: The median value of CA 19.9 was 103 U/mL (P25-75: 15;576), for a reference value <3 U/mL. No differences were found between sexes. A value of CA 19.9 >103 U/mL was associated with a lower level of survival at 3, 6, and 12 months (p=0.003, p=0.001, p=0.001, respectively) and with an older age at diagnosis (p=0.034). However, a high value of CA 19.9 was not a predictor of death. Twenty-six of 32 patients with CEA measurement presented higher values than normal (>3.8 ng/mL). There is no relationship between an elevated CEA and a value of CA 19.9 >103 U/mL. An increased level of CEA is not related to a higher level of survival at 12 months, but this relationship exists at 3 and 6 months (p=0.017). A value of CA 19.9 <103 U/mL at diagnosis was related to treatment with curative intent (surgery vs palliative chemotherapy), p=0.024. The probability of metastization at diagnosis was higher in individuals with values of CA 19.9 >103 U/mL. Conclusion: Serum levels of CA 19.9 >103 U/mL was related to the presence of metastization at diagnosis and lower levels of survival at 3, 6, and 12 months. Lower values of this tumor marker were associated with treatment of curative intention." @default.
• W2977332002 created "2019-10-10" @default.
• W2977332002 creator A5004143976 @default.
• W2977332002 creator A5004370490 @default.
• W2977332002 creator A5022631225 @default.
• W2977332002 creator A5024098480 @default.
• W2977332002 creator A5024379528 @default.
• W2977332002 creator A5041950395 @default.
• W2977332002 creator A5044741532 @default.
• W2977332002 creator A5053066053 @default.
• W2977332002 creator A5068633437 @default.
• W2977332002 creator A5077512170 @default.
• W2977332002 date "2014-10-01" @default.
• W2977332002 modified "2023-10-16" @default.
• W2977332002 title "Outcome in Cholangiocarcinoma: CA 19.9 as Marker of Survival and as Predictor of Metastization" @default.
• W2977332002 doi "https://doi.org/10.14309/00000434-201410002-00241" @default.
• W2977332002 hasPublicationYear "2014" @default.
• W2977332002 type Work @default.
• W2977332002 sameAs 2977332002 @default.
• W2977332002 citedByCount "0" @default.
• W2977332002 crossrefType "journal-article" @default.
• W2977332002 hasAuthorship W2977332002A5004143976 @default.
• W2977332002 hasAuthorship W2977332002A5004370490 @default.
• W2977332002 hasAuthorship W2977332002A5022631225 @default.
• W2977332002 hasAuthorship W2977332002A5024098480 @default.
• W2977332002 hasAuthorship W2977332002A5024379528 @default.
• W2977332002 hasAuthorship W2977332002A5041950395 @default.
• W2977332002 hasAuthorship W2977332002A5044741532 @default.
• W2977332002 hasAuthorship W2977332002A5053066053 @default.
• W2977332002 hasAuthorship W2977332002A5068633437 @default.
• W2977332002 hasAuthorship W2977332002A5077512170 @default.
• W2977332002 hasConcept C121608353 @default.
• W2977332002 hasConcept C126322002 @default.
• W2977332002 hasConcept C144369459 @default.
• W2977332002 hasConcept C167135981 @default.
• W2977332002 hasConcept C198433322 @default.
• W2977332002 hasConcept C2777387746 @default.
• W2977332002 hasConcept C2780210213 @default.
• W2977332002 hasConcept C2781447364 @default.
• W2977332002 hasConcept C3019719930 @default.
• W2977332002 hasConcept C71924100 @default.
• W2977332002 hasConcept C90924648 @default.
• W2977332002 hasConceptScore W2977332002C121608353 @default.
• W2977332002 hasConceptScore W2977332002C126322002 @default.
• W2977332002 hasConceptScore W2977332002C144369459 @default.
• W2977332002 hasConceptScore W2977332002C167135981 @default.
• W2977332002 hasConceptScore W2977332002C198433322 @default.
• W2977332002 hasConceptScore W2977332002C2777387746 @default.
• W2977332002 hasConceptScore W2977332002C2780210213 @default.
• W2977332002 hasConceptScore W2977332002C2781447364 @default.
• W2977332002 hasConceptScore W2977332002C3019719930 @default.
• W2977332002 hasConceptScore W2977332002C71924100 @default.
• W2977332002 hasConceptScore W2977332002C90924648 @default.
• W2977332002 hasLocation W29773320021 @default.
• W2977332002 hasOpenAccess W2977332002 @default.
• W2977332002 hasPrimaryLocation W29773320021 @default.
• W2977332002 hasRelatedWork W2224251873 @default.
• W2977332002 hasRelatedWork W2328572636 @default.
• W2977332002 hasRelatedWork W2380187705 @default.
• W2977332002 hasRelatedWork W2411030188 @default.
• W2977332002 hasRelatedWork W2411373641 @default.
• W2977332002 hasRelatedWork W2566798104 @default.
• W2977332002 hasRelatedWork W2977332002 @default.
• W2977332002 hasRelatedWork W3045563895 @default.
• W2977332002 hasRelatedWork W3149180470 @default.
• W2977332002 hasRelatedWork W233464004 @default.
• W2977332002 hasVolume "109" @default.
• W2977332002 isParatext "false" @default.
• W2977332002 isRetracted "false" @default.
• W2977332002 magId "2977332002" @default.
• W2977332002 workType "article" @default.